Form 4: Amicus Therapeutics Acquired by BioMarin for $14.50/Share

Amicus Therapeutics CEO Bradley L. Campbell reports the disposal of all equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.

Summary

• Bradley L. Campbell, President and CEO of Amicus Therapeutics (FOLD), disposed of 1,008,680 shares of common stock at $14.50 per share.
• The transaction was executed on April 27, 2026, in connection with the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.
• All outstanding stock options held by the reporting person were cancelled and converted into cash payments based on the $14.50 per share merger consideration.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the finalization of a previously announced corporate acquisition.

Positives

• Successful completion of the merger with BioMarin Pharmaceutical Inc.
• Full vesting of all restricted stock units and stock options in connection with the acquisition.

Negatives

• The company ceases to exist as an independent publicly traded entity following the acquisition.

Risks

• No ongoing risks as the issuer has been acquired.

Future Outlook

The company has been acquired by BioMarin Pharmaceutical Inc.; therefore, no further independent guidance or outlook is provided.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the rare disease and biotechnology sector, as BioMarin expands its portfolio through the absorption of Amicus Therapeutics.

Comparison to Industry Standards

• The acquisition price reflects standard premiums typically observed in biotech M&A activity.
• The conversion of unvested equity into cash upon change-of-control is consistent with standard executive compensation agreements in the pharmaceutical industry.

Stakeholder Impact

• Shareholders receive $14.50 per share in cash.
• Employees and management transition to the acquiring entity, BioMarin.

Next Steps

• Delisting of Amicus Therapeutics (FOLD) from public exchanges.

Key Dates

Keywords

Amicus Therapeutics, BioMarin, Merger, Acquisition, FOLD, Insider Transaction